Furthermore, expression of the CXCR4 ligand, CXCL12, by tumor-associated fibroblasts has been shown to promote immune evasion in a murine model of pancreatic cancer, while targeting CXCR4 with specific antagonist AMD3100 facilitated immunotherapy response in these model (97). Here, CXCL12 is linked to neoplasm.